DK2887923T3 - Oftalmisk opløsning af polyoxyllipid eller polyoxylfedtsyre og behandling af øjentilstande - Google Patents

Oftalmisk opløsning af polyoxyllipid eller polyoxylfedtsyre og behandling af øjentilstande Download PDF

Info

Publication number
DK2887923T3
DK2887923T3 DK13831463.8T DK13831463T DK2887923T3 DK 2887923 T3 DK2887923 T3 DK 2887923T3 DK 13831463 T DK13831463 T DK 13831463T DK 2887923 T3 DK2887923 T3 DK 2887923T3
Authority
DK
Denmark
Prior art keywords
polyoxyllipid
treatment
fatty acid
ophthalmic solution
eye conditions
Prior art date
Application number
DK13831463.8T
Other languages
English (en)
Inventor
Ashim K Mitra
Sidney L Weiss
Eugene J Mcnally
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50148510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2887923(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Application granted granted Critical
Publication of DK2887923T3 publication Critical patent/DK2887923T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK13831463.8T 2012-08-24 2013-08-23 Oftalmisk opløsning af polyoxyllipid eller polyoxylfedtsyre og behandling af øjentilstande DK2887923T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261693189P 2012-08-24 2012-08-24
PCT/US2013/056513 WO2014032026A1 (en) 2012-08-24 2013-08-23 Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions

Publications (1)

Publication Number Publication Date
DK2887923T3 true DK2887923T3 (da) 2023-07-03

Family

ID=50148510

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13831463.8T DK2887923T3 (da) 2012-08-24 2013-08-23 Oftalmisk opløsning af polyoxyllipid eller polyoxylfedtsyre og behandling af øjentilstande

Country Status (16)

Country Link
US (5) US8980839B2 (da)
EP (2) EP2887923B1 (da)
AU (1) AU2013305539B2 (da)
CA (2) CA2914472C (da)
DK (1) DK2887923T3 (da)
ES (1) ES2948387T3 (da)
FI (1) FI2887923T3 (da)
HK (1) HK1211867A1 (da)
HR (1) HRP20230559T1 (da)
HU (1) HUE062145T2 (da)
LT (1) LT2887923T (da)
MX (1) MX361858B (da)
PL (1) PL2887923T3 (da)
PT (1) PT2887923T (da)
SI (1) SI2887923T1 (da)
WO (1) WO2014032026A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2887923T (pt) 2012-08-24 2023-06-28 Sun Pharmaceutical Ind Ltd Formulação oftálmica de lípido de polioxil ou ácido gordo de polioxil e tratamento de condições oculares
WO2015179527A1 (en) * 2014-05-23 2015-11-26 Ocular Technologies Sarl Topical formulations and uses thereof
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
WO2016028800A1 (en) * 2014-08-20 2016-02-25 A.T. Resolve Sarl Treatment of corneal haze
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
KR101587412B1 (ko) 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
US20180133217A1 (en) * 2015-05-04 2018-05-17 Ocular Technologies Sarl Topical formulations and uses thereof
JP2018521000A (ja) 2015-05-29 2018-08-02 シドネキシス，インク． Ｄ２ｏで安定化された医薬製剤
EP3373976B1 (en) * 2015-11-10 2024-01-03 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
EP3373924A4 (en) * 2015-11-12 2019-06-19 Sun Pharma Global FZE TOPICAL FORMULATIONS AND USES THEREOF
MX2018010395A (es) 2016-02-29 2018-11-29 Sun Pharma Global Fze Formulaciones topicas que contienen cliclosporina y usos de las mismas.
WO2017190114A1 (en) 2016-04-29 2017-11-02 i-novion, Inc. Liquid pentablock co-polymer formulations for sustained delivery of therapeutics
KR102525438B1 (ko) * 2016-11-29 2023-04-26 오쿨리스 에스에이 안과용 활성 약학 성분 전달을 위한 고형 사이클로덱스트린 복합체의 제조
CN107334734B (zh) * 2017-07-10 2020-03-17 浙江大学 一种西罗莫司或其衍生物的眼用制剂
JP2023505409A (ja) * 2019-08-18 2023-02-09 アイビュー セラピューティクス（ズーハイ）カンパニー リミテッド 持続型の眼用薬物送達システムとしてシクロスポリンミセルを含むｉｎ－ｓｉｔｕゲル
BR112022011276A2 (pt) * 2019-12-09 2022-09-06 Univ Louisiana State Biomolécula para tratamento de patologias da córnea
AU2022295164A1 (en) 2021-06-14 2024-01-25 Sun Pharmaceutical Industries Limited Cyclosporine formulations for use in patients undergoing cataract surgery
IL310823A (en) * 2021-08-20 2024-04-01 Sun Pharmaceutical Ind Ltd Stable cyclosporine ophthalmic formulation and its manufacturing process

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2406A (en) * 1841-12-30 Construction of railroad-scbapers fob cleaning te-ie tracks from sl
FR520E (fr) 1901-11-13 1903-01-26 Bermont Victor Etienne Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5)
WO1993023010A1 (en) 1992-05-13 1993-11-25 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5484597A (en) 1993-07-30 1996-01-16 Chesebrough-Pond's Usa Co. Clear hydroalcholic cosmetic microemulsions
NZ280689A (en) * 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US6816968B1 (en) * 1998-07-10 2004-11-09 Silverbrook Research Pty Ltd Consumable authentication protocol and system
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
WO2001060778A2 (en) 2000-02-16 2001-08-23 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
DK1435910T3 (da) 2001-10-19 2009-11-09 Isotechnika Inc Nye cyclosporinanaloge mikroemulsionsprækoncentrater
AU2002365167A1 (en) 2001-12-18 2003-07-09 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
EP2022775B1 (en) 2002-04-01 2014-10-15 University of Southern California Trihydroxy polyunsaturated eicosanoids
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
DK2216318T3 (da) 2002-08-12 2018-12-10 Brigham & Womens Hospital Resolvins: Bioskabeloner til terapeutiske indgreb
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
US20040213782A1 (en) 2003-02-03 2004-10-28 Pharmacia Corporation Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
JP2004238346A (ja) * 2003-02-07 2004-08-26 Shiono Chemical Co Ltd トラニラストの安定な水溶液製剤
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
AU2003228126A1 (en) 2003-05-02 2004-11-23 Arturo Jimenez Bayardo Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
WO2005105025A1 (en) 2004-04-14 2005-11-10 Boston University Methods and compositions for preventing or treating periodontal diseases
US20060020563A1 (en) * 2004-07-26 2006-01-26 Coleman Christopher R Supervised neural network for encoding continuous curves
ATE412400T1 (de) * 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
AU2005306320B2 (en) 2004-11-19 2011-09-08 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
CN101193634A (zh) 2005-06-09 2008-06-04 参天制药株式会社 罗氟司特滴眼液
AU2006259261B2 (en) 2005-06-16 2013-06-13 Myrexis, Inc. Pharmaceutical compositions and use thereof
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
PL1904056T3 (pl) 2005-07-18 2009-09-30 Minu Llc Zastosowanie makrolidu do przywracania czucia rogówkowego
WO2007090162A2 (en) 2006-01-31 2007-08-09 Martek Biosciences Corporation OXYLIPINS FROM STEARIDONIC ACID AND γ-LINOLENIC ACID AND METHODS OF MAKING AND USING THE SAME
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
FR2904568B1 (fr) * 2006-08-03 2008-09-05 Dynastar Skis Sa Procede de fabrication d'une planche de glisse
JP2010519311A (ja) 2007-02-20 2010-06-03 マーテック バイオサイエンシーズ コーポレーション 長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製およびその使用方法
US20100310462A1 (en) 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US8512687B2 (en) * 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US20090048929A1 (en) * 2007-08-15 2009-02-19 Paul Im Authenticated travel record
KR101529093B1 (ko) 2007-08-29 2015-06-16 와카모토 세이야꾸 가부시끼가이샤 라타노프로스트 함유 수성 의약 조성물
MX2007011165A (es) 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
ES2667945T3 (es) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
EP2234629A4 (en) * 2008-01-04 2011-05-25 Alcon Pharmaceuticals Ltd STABLE AQUEOUS CYCLOSPORIN COMPOSITIONS
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
CA2725523C (en) * 2008-05-28 2017-01-10 Alcon Research, Ltd. Self-preserved emulsions
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
WO2010141069A2 (en) * 2009-06-02 2010-12-09 Wu Nian Pure peg-lipid conjugates
JP2012529509A (ja) 2009-06-09 2012-11-22 ラックス・バイオサイエンシーズ・インコーポレイテッド 眼科用用途のための局所薬物送達システム
CA2773597A1 (en) * 2009-09-17 2011-03-24 Senju Pharmaceutical Co., Ltd. Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US9328162B2 (en) 2010-02-25 2016-05-03 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
JP2013525508A (ja) 2010-05-07 2013-06-20 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッド 新規な点眼組成物
US20130065888A1 (en) 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
EP2846769A1 (en) 2012-05-11 2015-03-18 Cipla Limited Pharmaceutical composition
PT2887923T (pt) 2012-08-24 2023-06-28 Sun Pharmaceutical Ind Ltd Formulação oftálmica de lípido de polioxil ou ácido gordo de polioxil e tratamento de condições oculares
US10946076B2 (en) 2013-02-13 2021-03-16 The Research Foundation For The State University Of New York Glaucoma treatment
WO2015179527A1 (en) 2014-05-23 2015-11-26 Ocular Technologies Sarl Topical formulations and uses thereof
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20180133217A1 (en) 2015-05-04 2018-05-17 Ocular Technologies Sarl Topical formulations and uses thereof
EP3373976B1 (en) 2015-11-10 2024-01-03 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
EP3373924A4 (en) 2015-11-12 2019-06-19 Sun Pharma Global FZE TOPICAL FORMULATIONS AND USES THEREOF
MX2018010395A (es) 2016-02-29 2018-11-29 Sun Pharma Global Fze Formulaciones topicas que contienen cliclosporina y usos de las mismas.
WO2017152129A2 (en) 2016-03-03 2017-09-08 Ocular Technologies Sarl Treatment of glaucoma and/or retinal diseases and formulations useful therefore

Also Published As

Publication number Publication date
SI2887923T1 (sl) 2023-09-29
US8980839B2 (en) 2015-03-17
MX2015002239A (es) 2016-01-08
CA2914472C (en) 2019-09-03
HK1211867A1 (en) 2016-06-03
EP2887923B1 (en) 2023-04-05
PL2887923T3 (pl) 2023-08-14
EP2887923A4 (en) 2016-03-30
WO2014032026A1 (en) 2014-02-27
US20140057854A1 (en) 2014-02-27
CA2914472A1 (en) 2014-02-27
AU2013305539B2 (en) 2018-08-02
FI2887923T3 (fi) 2023-06-30
CA3050298A1 (en) 2014-02-27
AU2013305539A1 (en) 2015-03-12
MX361858B (es) 2018-12-18
US20160256520A1 (en) 2016-09-08
EP2887923A1 (en) 2015-07-01
PT2887923T (pt) 2023-06-28
US20150148299A1 (en) 2015-05-28
LT2887923T (lt) 2023-07-10
US9937225B2 (en) 2018-04-10
HRP20230559T1 (hr) 2023-09-15
US20160256521A1 (en) 2016-09-08
ES2948387T3 (es) 2023-09-11
HUE062145T2 (hu) 2023-10-28
US10441630B2 (en) 2019-10-15
US20150165048A1 (en) 2015-06-18
EP4218729A1 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
DK2887923T3 (da) Oftalmisk opløsning af polyoxyllipid eller polyoxylfedtsyre og behandling af øjentilstande
BR112012032948A2 (pt) dispositivos injectores e método de suprimento de solução oftálmica à córnea do olho
DK3295942T3 (da) Kombinationer omfattende 5-phenoxy-3h-pyrimidin-4-on-derivater og anvendelse heraf til profylakse eller behandling af hiv-infektion
DK3495387T3 (da) Bispecifikke anti-VEGF-/anti-ANG-2-antistoffer og deres anvendelse ved behandling af okulære vaskulære sygdomme
DK2882441T3 (da) Behandling af immunrelaterede og inflammatoriske sygdomme
DK2877184T3 (da) Sammensætninger og behandling for øjensygdomme og -lidelser
BR112015002548A2 (pt) máscara ocular
DK2882496T3 (da) Behandling og diagnosticering af melanom
DK2747763T3 (da) (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser
DK2892912T3 (da) C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
DK3290024T3 (da) Vedvarende indgivelse af aktive midler til behandling af glaukom og okulær hypertension
DK2903967T6 (da) Acylaminopyrimidinderivater til behandling af virusinfektioner og andre sygdomme
DK2846809T3 (da) Behandling af myelosuppression
DK2917358T3 (da) Sammensætninger og fremgangsmåder til biologisk fremstilling af fedtsyrederivater
DK2800575T3 (da) Behandling af subarachnoidalblødning og iskæmi
FR2995214B1 (fr) Solution a viscosite reduite de proteine a concentration elevee
BR112013034054A2 (pt) ésteres para tratamento de condições inflamatórias oculares
DK2903432T3 (da) Fremgangsmåde til behandling af sædceller til kønsortering
DK3470018T3 (da) Kryokonservering af levedygtige menneskehudssubstitutter
DK2854910T3 (da) Ceramidniveauer i behandling og forebyggelse af infektioner
DK2880053T3 (da) Lindring af vævsskade og fibrose via anti-LTBP4-antistof
DK3060908T3 (da) Diagnosticering og behandling af autoimmune sygdomme
DK2576782T3 (da) Sirna og anvendelse deraf i fremgangsmåder og sammensætninger til behandling og/eller forebyggelse af øjentilstande
DK2892556T3 (da) Sammensætninger og fremgangsmåder til behandling af sygdomme
SMT201700030B (it) Capsula e dispositivo di trattamento di detta capsula